UPDATE 1-U.S. FDA approves Lundbeck's migraine prevention therapy
February 21, 2020 at 20:02 PM EST
The U.S. Food and Drug Administration approved Lundbeck A/S' migraine prevention therapy, which the Danish drugmaker acquired through its near $2 billion deal for Alder BioPharmaceuticals in 2019, the company said on Friday.